Maduck Sean sold $1.8M of CORT
Maduck Sean (See Remarks) sold 25,000 shares of CORCEPT THERAPEUTICS INC (CORT) at an average of $70.21 ($70.11–$70.75, $1.76M total) across 2 trades on 2026-06-01 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The disclosed sale adds new information about insider sentiment for Corcept Therapeutics.
Market read
The filing introduces fresh data that traders may use to adjust short‑term positions in CORT.
What to watch
Potential upcoming clinical data or financing events not disclosed in the filing.
Background
Form 4 filings provide the first public disclosure of insider transactions.
Ticker impact
Officer Maduck Sean sold 25,000 shares for $1.75M via a 10b5‑1 plan.
likely pressure as the market prices in the insider sell
A $1.8M sale by an officer is material for a small‑cap biotech and often leads to short‑term downside.
Market effects
May raise caution for other small‑cap biotech stocks with insider sales.
Limited to U.S. biotech sector.
Minimal global impact.
Counterpoint
The sale could be routine under a 10b5‑1 plan and not reflect negative sentiment.
Key entities
- CompanyCorcept Therapeutics Inc.
Biopharmaceutical company developing therapies for cortisol‑related disorders.
- OfficerMaduck Sean
Company officer executing a pre‑arranged 10b5‑1 sale.
